Medtronic plc ( MDT Quick Quote MDT - Free Report) announced positive results from two analyses conducted on AdaptivCRT algorithm at the European Heart Rhythm Association (“EHRA”) Scientific Sessions 2018 in Barcelona, Spain.
The study demonstrated that AdaptivCRT algorithm reduces atrial fibrillation ("AF") episodes, along with higher patient activity levels. The results were based on 408 heart failure patients with Medtronic cardiac resynchronization therapy ("CRT") device at 26 centers in Italy.
The first study showed a significant reduction in the occurrence of AF episodes of all measured durations in 210 patients with AdaptivCRT ON compared to 198 patients with traditional CRT.
The second study revealed AdaptivCRT was linked with a higher daily activity level for patients with the feature ON compared to patients with conventional CRT.
Per the company, CRT is an established treatment for patients with heart failure who use an implantable defibrillator (CRT-D) or pacemaker (CRT-P) to enhance the heart’s pumping efficiency.
The AdaptivCRT Platform at a Glance
In medicine, a CRT resynchronizes the contractions of heart's ventricles by sending electrical impulses to the heart muscle. Thus, CRT helps the heart pump blood throughout the body more efficiently and is a very promising technique in the markets of cardiac rhythm management and heart failure.
Medtronic’s AdaptivCRT platform minutely evaluates cardiac rhythms on the back of two pacing operations, namely, Adaptive LV and Adaptive Bi-V.
Of the major CRT platforms of Medtronic, Claria MRI CRT-D SureScan and Percepta CRT-P MRI SureScan deserve a mention.
Developments in Cardiac Rhythm and Heart Failure Division
The company is consistently trying to improve its Cardiac Rhythm and Heart Failure division — part of Cardiac & Vascular Group (CVG). In line with this, Medtronic recently announced the receipt of FDA approval and commercial launch of its portfolio of Azure pacemakers with BlueSync technology.
In May 2017, Medtronic received the FDA’s approval for quadripolar cardiac resynchronization therapy-pacemakers (CRT-Ps) that improve therapy delivery for patients with heart failure.
Per a GlobalData report, the global heart failure market is set to reach a worth of $11.8 billion by 2025, at a CAGR of 13.7%. Considering the bullish market sentiments, we believe that the latest development is a timely one.
Stock Performance & Estimate Revision
Over the past month, shares of Medtronic have underperformed the
industry. The stock has dipped 0.6% as against the industry’s 2.5% and the S&P 500 index’s 0.2% gain.
Also, the estimate revision trend for the current year is unfavorable with 12 estimates moving south over the last two months compared with one in the opposite direction. Earnings estimates fell around 0.4% to $4.75 per share.
Zacks Rank & Key Picks
Medtronic carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Bio-Rad Laboratories
BIO, athenahealth, Inc. ATHN and Varian Medical Systems, Inc. VAR.
Bio-Rad Laboratories sports a Zacks Rank of 1 (Strong Buy). You can see
The company has a long-term expected earnings growth rate of 20%. the complete list of today’s Zacks #1 Rank stocks here.
athenahealth is another Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
Varian Medical has a long-term expected earnings growth rate of 8%. The stock carries a Zacks Rank #2 (Buy).
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >>